Figure 2.
![Figure 2. CRCL vaccine generates tumor-specific immunity. (A) Immunization with 12B1-derived CRCL provides specificity protection against 12B1 tumor challenge. BALB/c mice were immunized with 20 μg 12B1- or A20 tumor–derived CRCL, on days - 14 and - 7, followed by challenge with 103 12B1 cells (LD100) in the opposite groin on day 0 (saline versus CRCL [12B1], P < .05 from day 15 onward; n = 11-24 mice per group). (B) Immunization with purified HSP70 or CRCL from 12B1 tumor delays tumor growth. Mice were immunized with 20 μg 12B1 tumor–derived HSP70 or CRCL or unfractionated lysate on days - 14 and - 7 followed by challenge with 103 12B1 cells in the opposite groin on day 0 (saline vs HSP70 or CRCL, P < .05 from day 15 onward; n = 8 mice per group).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/101/11/10.1182_blood-2002-10-3108/5/h81134417002.jpeg?Expires=1722711601&Signature=KtA9W2f23N-enJKS9FxGtDmFRChGsHtE6R1G5e9igzRgXRhTkHCnN~qRajZcoMMI~RwIrkg55MzwRoh87~~vy4YfwAtXiv5Oh-SWnHPYqz2LzeOJ69uNqdpbZ44yz0GQWeRk1ksp9XnWXF2-WVH63-RcNs6F~zGuHvOtu8m~2-82hQg8C5zirqJRe1R7~lNdPgg9QskBu0qCsIC9bjfhungo--QSJlPtnvH~ATBmbb-i4kXAGAgFBxCAsTopv6WrP~66YMxd7A8sydW4c2Sp1M0UwRB-f2~5lyYwfQM807b0cFWXbUfbe1Cx8jTGTyYMci6-8xr3P4QGMrJILQtjfw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CRCL vaccine generates tumor-specific immunity. (A) Immunization with 12B1-derived CRCL provides specificity protection against 12B1 tumor challenge. BALB/c mice were immunized with 20 μg 12B1- or A20 tumor–derived CRCL, on days - 14 and - 7, followed by challenge with 103 12B1 cells (LD100) in the opposite groin on day 0 (saline versus CRCL [12B1], P < .05 from day 15 onward; n = 11-24 mice per group). (B) Immunization with purified HSP70 or CRCL from 12B1 tumor delays tumor growth. Mice were immunized with 20 μg 12B1 tumor–derived HSP70 or CRCL or unfractionated lysate on days - 14 and - 7 followed by challenge with 103 12B1 cells in the opposite groin on day 0 (saline vs HSP70 or CRCL, P < .05 from day 15 onward; n = 8 mice per group).
